nobiletin has been researched along with Cancer of Kidney in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, D; Ge, J; Tang, C; Wu, D; Xu, Z; Zhang, Z; Zhou, W | 1 |
| Chen, T; Fu, W; Hu, X; Liu, L; Luo, X; Xu, J; Zhang, W; Zhou, T; Zou, Y | 1 |
2 other study(ies) available for nobiletin and Cancer of Kidney
| Article | Year |
|---|---|
Nobiletin inhibits viability of human renal carcinoma cells via the JAK2/STAT3 and PI3K/Akt pathway.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Flavones; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 2; Kidney Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; STAT3 Transcription Factor | 2020 |
Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Female; Flavones; G1 Phase Cell Cycle Checkpoints; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Piperazines; Pyridines; S-Phase Kinase-Associated Proteins; Signal Transduction | 2021 |